托珠单抗在大动脉炎中的显著疗效。
A Spectacular Effect of Tocilizumab in Takayasu Arteritis.
作者信息
Saïd Fatma, Naceur Ines, Ben Achour Tayssir, Jridi Maysam, Smiti Monia
机构信息
Internal Medicine, University Hospital La Rabta, Tunis, Tunisia.
Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.
出版信息
Eur J Case Rep Intern Med. 2024 Nov 7;11(12):004868. doi: 10.12890/2024_004868. eCollection 2024.
BACKGROUND
Anti-interleukin-6 receptors (anti-IL-6R) have been a promising new therapeutic alternative in the treatment of Takayasu arteritis.
CASE DESCRIPTION
We report the case of a 34-year-old patient with Takayasu arteritis diagnosed in 2017. While she was on corticosteroid and methotrexate, the patient presented twice with clinical and radiological signs of activity, requiring an increase of corticosteroid dose and an increase in the methotrexate dose to 20 mg/week. Anti-IL-6R infusions were indicated. At the end of the fifth infusion, the patient was totally asymptomatic: she no longer experienced episodes of syncope or amnesia.
CONCLUSION
Our case perfectly illustrates the effectiveness of anti-IL-6R in the treatment of Takayasu arteritis, especially in its refractory form.
LEARNING POINTS
Takayasu arteritis may have a significant functional impact that affects quality of life.Tocilizumab is a very interesting therapeutic alternative in the refractory form of Takayasu arteritis.
背景
抗白细胞介素-6受体（抗IL-6R）已成为治疗大动脉炎的一种有前景的新型治疗选择。
病例描述
我们报告一例2017年诊断为大动脉炎的34岁患者。在使用皮质类固醇和甲氨蝶呤治疗期间，该患者两次出现临床和影像学活动征象，需要增加皮质类固醇剂量并将甲氨蝶呤剂量增至20mg/周。遂开始使用抗IL-6R输注治疗。在第五次输注结束时，患者完全无症状：她不再经历晕厥或失忆发作。
结论
我们的病例完美地说明了抗IL-6R在治疗大动脉炎，尤其是难治性大动脉炎中的有效性。
学习要点
大动脉炎可能对功能有重大影响，进而影响生活质量。托珠单抗是难治性大动脉炎一种非常有吸引力的治疗选择。
Zotero 插件